MX2023004677A - Moduladores de la via de respuesta integrada al estres. - Google Patents
Moduladores de la via de respuesta integrada al estres.Info
- Publication number
- MX2023004677A MX2023004677A MX2023004677A MX2023004677A MX2023004677A MX 2023004677 A MX2023004677 A MX 2023004677A MX 2023004677 A MX2023004677 A MX 2023004677A MX 2023004677 A MX2023004677 A MX 2023004677A MX 2023004677 A MX2023004677 A MX 2023004677A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- stress response
- modulators
- integrated stress
- response pathway
- Prior art date
Links
- 230000009221 stress response pathway Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003938 response to stress Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos con la fórmula (I) (ver Fórmula) (I) o sales aceptables desde el punto de vista farmacéutico, solvatos, hidratos, tautómeros o estereoisómeros de los mismos, en donde R1, R2, R3, R4a, R4b, R4c, R4d, R4f, X1, X2 tienen el significado tal como se indica en la descripción y reivindicaciones. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos, su uso como medicamento y en un método para el tratamiento o prevención de una o más enfermedades o trastornos asociados a una respuesta integrada al estrés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20203311 | 2020-10-22 | ||
| EP21192154 | 2021-08-19 | ||
| PCT/EP2021/079209 WO2022084447A1 (en) | 2020-10-22 | 2021-10-21 | Modulators of the integrated stress response pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004677A true MX2023004677A (es) | 2023-05-24 |
Family
ID=78402117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004677A MX2023004677A (es) | 2020-10-22 | 2021-10-21 | Moduladores de la via de respuesta integrada al estres. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391763A1 (es) |
| EP (1) | EP4232447A1 (es) |
| JP (1) | JP2023546226A (es) |
| KR (1) | KR20230110510A (es) |
| AU (1) | AU2021363616A1 (es) |
| CA (1) | CA3195292A1 (es) |
| IL (1) | IL302219A (es) |
| MX (1) | MX2023004677A (es) |
| WO (1) | WO2022084447A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968347B1 (en) | 2013-03-15 | 2023-08-02 | The Regents of the University of California | Modulators of the eif2alpha pathway |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| EP3468948A1 (en) | 2016-06-08 | 2019-04-17 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| EP3558980B1 (en) * | 2016-12-23 | 2021-01-27 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Compounds for use in the treatment of kinetoplastid infection |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2019008507A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2- (4-CHLOROPHENOXY) -N - ((1- (2- (4-CHLOROPHENOXY) ETHYNAZETIDIN-3-YL) METHYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF ATF4 FOR THE TREATMENT OF CANCER AND D OTHER DISEASES |
| BR112020000122A2 (pt) | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| CN118239938A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| MA50063A (fr) | 2017-09-01 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| WO2019090090A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| US20210205277A1 (en) | 2017-11-02 | 2021-07-08 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704089B1 (en) | 2017-11-02 | 2023-07-19 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| AU2018360850A1 (en) | 2017-11-02 | 2020-06-11 | Abbvie Inc. | Modulators of the integrated stress pathway |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| CN112424167A (zh) | 2018-07-09 | 2021-02-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 化学化合物 |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| PE20212023A1 (es) | 2019-02-13 | 2021-10-18 | Denali Therapeutics Inc | Compuestos, composiciones y metodos |
| WO2020167994A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202107871UA (en) | 2019-02-25 | 2021-08-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20220004105A (ko) | 2019-04-23 | 2022-01-11 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| SG11202111362SA (en) | 2019-04-23 | 2021-11-29 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| SG11202111918PA (en) | 2019-04-30 | 2021-11-29 | Calico Life Sciences Llc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| JP2022530647A (ja) | 2019-04-30 | 2022-06-30 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の置換シクロアルキルモジュレーター |
| JP2022536901A (ja) | 2019-06-12 | 2022-08-22 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| MX2022009243A (es) | 2020-01-28 | 2022-08-16 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| CA3165813A1 (en) | 2020-03-11 | 2021-09-16 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
-
2021
- 2021-10-21 JP JP2023524308A patent/JP2023546226A/ja active Pending
- 2021-10-21 IL IL302219A patent/IL302219A/en unknown
- 2021-10-21 KR KR1020237016361A patent/KR20230110510A/ko active Search and Examination
- 2021-10-21 WO PCT/EP2021/079209 patent/WO2022084447A1/en active Application Filing
- 2021-10-21 CA CA3195292A patent/CA3195292A1/en active Pending
- 2021-10-21 AU AU2021363616A patent/AU2021363616A1/en active Pending
- 2021-10-21 EP EP21798643.9A patent/EP4232447A1/en active Pending
- 2021-10-21 US US18/033,312 patent/US20230391763A1/en active Pending
- 2021-10-21 MX MX2023004677A patent/MX2023004677A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230391763A1 (en) | 2023-12-07 |
| CA3195292A1 (en) | 2022-04-28 |
| AU2021363616A1 (en) | 2023-06-22 |
| IL302219A (en) | 2023-06-01 |
| JP2023546226A (ja) | 2023-11-01 |
| WO2022084447A1 (en) | 2022-04-28 |
| EP4232447A1 (en) | 2023-08-30 |
| KR20230110510A (ko) | 2023-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012903A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| MX2022009243A (es) | Moduladores de la via de respuesta integrada al estres. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| NO20051265L (no) | Anvendelse av og noen nye imidazopyridiner | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| HK1146049A1 (en) | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | |
| MX2022011143A (es) | Moduladores de la via de respuesta integrada al estres. | |
| SE0202429D0 (sv) | Novel Compounds | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| CR20220638A (es) | Derivados de amidopirimidona | |
| PH12021551035A1 (en) | Pyrazoles as modulators of hemoglobin | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| MX2023004677A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2024000043A (es) | Compuestos inhibidores de la caspasa-2. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| MX2023004626A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2023004623A (es) | Moduladores de la via integrada de respuesta al estres. | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| CR20230331A (es) | Derivados de pirazolamida |